The role of screening and treatment in national progress toward hepatitis C elimination — Georgia, 2015–2016

Morbidity and Mortality Weekly Report

Volumn 66, Issue 29, 2017, Pages 773-776

  Nasrullah, Muazzam ^a   Sergeenko, David ^b   Gvinjilia, Lia ^c   Gamkrelidze, Amiran ^d   Tsertsvadze, Tengiz ^e   Butsashvili, Maia ^f   Metreveli, David ^g   Sharvadze, Lali ^h   Alkhazashvili, Maia ^d   Shadaker, Shaun ^c   Ward, John W ^a   Morgan, Juliette ^i,j   Averhoff, Francisco ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b National Center for Disease Control and Public Health of Georgia Ministry of Labor Health and Social Affairs of Georgia   (United States)

^c CDC FOUNDATION   (United States)

^d National Center for DiseaseControl and Public Health of Georgia   (United States)

^e Division of STD Prevention   (United States)

^f Neolab   (United States)

^g Medical Center Mrcheveli   (United States)

^h Joint Georgian French Hepatology Clinic Hepa   (United States)

ⁱ Mailstop D 69   (United States)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; DISEASE ERADICATION; FEMALE; GEORGIA; HEPATITIS C; HUMAN; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROGRAM EVALUATION; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DISEASE ERADICATION; FEMALE; GEORGIA; HEPATITIS C; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROGRAM EVALUATION; UNITED STATES; YOUNG ADULT;

EID: 85026636444     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6629a2     Document Type: Article

References (8)

1. Mitruka K, Tsertsvadze T, Butsashvili M, et al. Launch of a nationwide hepatitis C elimination program—Georgia, April 2015. MMWR Morb Mortal Wkly Rep 2015;64:753–7. https://doi.org/10.15585/mmwr.mm6428a2
2. Gvinjilia L, Nasrullah M, Sergeenko D, et al. National progress toward hepatitis C elimination—Georgia, 2015–2016. MMWR Morb Mortal Wkly Rep 2016;65:1132–5. https://doi.org/10.15585/mmwr.mm6541a2
3. Bedossa P, Poynard T; The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289–93. https://doi.org/10.1002/hep.510240201
4. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32–6. https://doi.org/10.1002/ hep.21669
5. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky VM, Miller V; Definitions/Nomenclature Working Group of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research. Recommendations for standardized nomenclature and definitions of viral response in trial of hepatitis C virus investigational agents. Hepatology 2012;56:2398–403. https://doi.org/10.1002/hep.25888
6. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015;62(Suppl):S87–99. https://doi.org/10.1016/j.jhep.2015.02.006
7. Ministry of Labour Health and Social Affairs of Georgia. Strategic plan for the elimination of hepatitis C virus in Georgia, 2016–2020. Tbilisi, Georgia: Ministry of Labour Health and Social Affairs; 2017. http://moh.gov.ge/ka/528/
8. World Health Organization. Global hepatitis report, 2017. Geneva, Switzerland: World Health Organization; 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1